Second-line erlotinib in an EGFR mutation-negative patient with non-small-cell lung cancer it might be difficult to obtain further specimens or the patient might dislike the idea of re-biopsy.
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VH has received honoraria from Hofmann-La Roche and AstraZeneca Pharmaceuticals for participation on advisory boards. I agree with the statement in this publication that tyrosine kinase inhibitors (tkis) against the epidermal growth factor receptor (egfr) should be considered "for all [non-small-cell lung cancer (nsclc)] patients in the second-line, third-line, or maintenance setting, including those patients who are EGFR mutationnegative." But it is vital to remember that not all such patients are eligible for egfr tkis. Patients with malabsorption, nausea and vomiting, diarrhea, skin disease (rash), or interstitial lung disease are not good candidates for this treatment.
Mutations other than those on exon 19 or 21, the most frequent mutations of EGFR (as mentioned in the publication), are not routinely tested for. Would exon 18 or other EGFR mutations be positive in this patient? We rarely re-biopsy tumours at the time of disease progression, especially at the time of new metastatic disease after treatment failure. We have learned that mutations of resistance can develop 1 and that metastatic lesions do not necessarily have the same characteristics as the primary tumour. At the time of diagnosis, some tumours are combined small-cell and non-small-cell, but the small-cell component is not detected in the original biopsy. In the re-biopsy specimen, after disease progression, only small-cell tumor may be found 2 . As additional specific targeted agents are developed for each line of treatment, individualized treatment based on new biopsy results will be more appropriate, even though Curr Oncol, Vol. 19, pp. 21-22; doi: http://dx.doi.org/10.3747/co.19.959
